Scientists from Japan and Switzerland report that an experimental vaccine for Alzheimer disease reduces brain deposits of β-amyloid (Aβ) protein, a hallmark of the disease, in a mouse model for the disorder (Okura Y et al. Proc Natl Acad Sci U S A. 2006;103:9619-9624). Previous studies with an Aβ peptide vaccine found that reducing plaques in such mice was associated with recovery of cognitive deficits; however, a clinical trial of this type of vaccine was halted because some patients developed brain inflammation.
Stephenson J. Alzheimer Vaccine Study. JAMA. 2006;296(3):272. doi:10.1001/jama.296.3.272-a